# Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

> **NCT02281318** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 556 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** Mepolizumab
- **DRUG:** Placebo
- **DRUG:** SOC

## Key facts

- **NCT ID:** NCT02281318
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-11
- **Primary completion:** 2016-06-10
- **Final completion:** 2016-06-10
- **Target enrollment:** 556 (ACTUAL)
- **Last updated:** 2018-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02281318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02281318, "Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT02281318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*